Clinical trials of targeted therapy in the treatment of RAI failure or advanced DTC

VernacularTitle:靶向治疗在RAI治疗失败或晚期DTC中的临床试验研究
Author: Haifeng SUN ; Yahuan GUO ; Zizhang WANG ; Fengsheng LI
Keywords: Thyroid neoplasms/TH; Review
From: Journal of Chinese Physician 2017;19(4):629-633
CountryChina
Language:Chinese
Abstract: Regarding radioactive iodine-refractory failure or advanced differentiated thyroid cancer,multiple multikinase inhibitors including sorafenib and lenvatinib,which target platelet derived growth factor receptor,vascular endothelial growth factor pathway,and rearranged during transfection (RET) pathway were proved to have obvious antitumor activity.Moreover,selective BRAF inhibitor,promoting drug uptake of radioactive iodine also showed a certain therapeutic effect.These molecular targets which are relevant with differentiated thyroid cancer occurrence,development,invasion and metastasis have become of its moment,and,selective inhibitors and re-differentiation agents were shown to be promising.In the future,individual genetic testing would provide more specific information in directing individualized molecular-targeted therapy.